Longtime Intercept CEO Mark Pruzanski departs as ailing NASH company tries to find its future

Mark Pruzanski, the CEO who turned “NASH” into a household name around biotech, guided his company to the precipice of a nascent field and then watched it falter in the wake of a CRL, will step down on January.